SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. ONCTa clinical-stage biopharmaceutical company focused on developing novel oncology therapies, announced today that it will report third quarter 2022 financial results after U.S. financial markets closed on Thursday, November 3, 2022 to have. Oncternal management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and to discuss the company’s financial results.
The live webcast of the conference call is available online at investor.oncternal.com and the call will be archived there for at least 30 days.
About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies to treat cancer patients with critical unmet medical needs. Oncternal pursues drug development targeting promising uncharted biological pathways involved in cancer development or progression, with a focus on hematological malignancies and prostate cancer. The leading clinical program is zilovertamab, an investigational monoclonal antibody designed to inhibit receptor tyrosine kinase-like orphan receptor 1 (ROR1) function. ZILO-301, a global phase 3 study evaluating zilovertamab in combination with ibrutinib for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL), has started (NCT05431179). Zilovertamab continues to be evaluated in an ongoing Phase 1/2 study in combination with ibrutinib for the treatment of patients with MCL and chronic lymphocytic leukemia (CLL), and this study was recently expanded to include patients with marginal zone lymphoma (MZL). Zilovertamab is also being studied in two investigator-initiated studies, including a Phase 2 clinical study of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL and a Phase 1b study of zilovertamab in combination with docetaxel in…
